Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Science Signaling
|
December 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i>-driven lung cancer by concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Blood
|
June 18, 2011
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
Karoline V Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, et al.
Cell Chemical Biology
|
July 30, 2021
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors
Vinayak Palve, Claire E Knezevic, Daniel S Bejan, et al.
Science Signaling
|
February 14, 2019
An immunoproteomic approach to characterize the CAR interactome and signalosome
Maria C Ramello, Ismahène Benzaïd, Brent M Kuenzi, et al.
Blood
|
January 9, 2008
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils
Michael Kneidinger, Uwe Schmidt, Uwe Rix, et al.
Molecular Systems Biology
|
February 21, 2015
Targeting a cell state common to triple-negative breast cancers
Markus K Muellner, Barbara Mair, Yasir Ibrahim, et al.
Molecular Systems Biology
|
November 6, 2013
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
Jiannong Li, Keiryn Bennett, Alexey Stukalov, et al.
Science Signaling
|
August 16, 2022
IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells
Lily L Remsing Rix, Natalia J Sumi, Qianqian Hu, et al.
Cancer Research
|
April 22, 2017
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Aria Vaishnavi, Laura Schubert, Uwe Rix, et al.
Cancer Immunology Research
|
March 3, 2021
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity
Manali S Phadke, Zhihua Chen, Jiannong Li, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Science Signaling
|
December 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i>-driven lung cancer by concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Blood
|
June 18, 2011
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
Karoline V Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, et al.
Cell Chemical Biology
|
July 30, 2021
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors
Vinayak Palve, Claire E Knezevic, Daniel S Bejan, et al.
Science Signaling
|
February 14, 2019
An immunoproteomic approach to characterize the CAR interactome and signalosome
Maria C Ramello, Ismahène Benzaïd, Brent M Kuenzi, et al.
Blood
|
January 9, 2008
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils
Michael Kneidinger, Uwe Schmidt, Uwe Rix, et al.
Molecular Systems Biology
|
February 21, 2015
Targeting a cell state common to triple-negative breast cancers
Markus K Muellner, Barbara Mair, Yasir Ibrahim, et al.
Molecular Systems Biology
|
November 6, 2013
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
Jiannong Li, Keiryn Bennett, Alexey Stukalov, et al.
Science Signaling
|
August 16, 2022
IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells
Lily L Remsing Rix, Natalia J Sumi, Qianqian Hu, et al.
Cancer Research
|
April 22, 2017
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Aria Vaishnavi, Laura Schubert, Uwe Rix, et al.
Cancer Immunology Research
|
March 3, 2021
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity
Manali S Phadke, Zhihua Chen, Jiannong Li, et al.
Page
of 9